How to Order 2018-06-26T14:45:44+00:00

One Sample. Three Easy Steps to Order.

1. Request complimentary ThyGenX®/ThyraMIR™ Sample Collection Kits

Kits contain all the materials needed to order ThyGenX® and ThyraMIR™, including a test requisition form, RNARetain®*, shipping materials, and prepaid return postage. To order supplies, contact your representative or call Client Services at 844-405-9655.

ThyGenX® and ThyraMIR™ allows for flexibility to use your local cytopathology lab or send samples to Interpace (FNA or cytology slides)

2. Collect a specimen for testing when performing FNA

  • Perform a dedicated FNA pass and then add FNA specimen to RNARetain®.
  • One pap stained or DifQuick stain cytology smear is also accepted.
  • Preserved specimen can be held at room temperature for up to 6 weeks while determining the need for molecular analysis.
  • Refrigeration is not required for storing or shipping.
  • Testing available from cytology slides

3. Mail the samples and requisition form

  • Complete the requisition form and include a copy of the patient’s insurance card or face sheet.
  • Be sure to select the test(s) desired on the requisition form.

Turnaround Time

Expect a ThyGenX® and ThyraMIR™ report delivered within 10 to 14 business days from the date of the requisition form and sample submission.

International Orders

We accept international orders. Please contact us to find out how to order from outside of the US.


Limitations and Disclaimers:

The ThyraMIR™ microRNA Classifier and the ThyGenX® Oncogene Panel each consist of markers strongly associated with thyroid cancer and whose detection in preoperative thyroid nodule aspirations have been shown to be highly predictive for thyroid cancer. These tests are intended to aid in the diagnosis of thyroid nodules with indeterminate cytology; positive or negative test results should be interpreted in conjunction with all other available clinical data. These tests were developed and performance characteristics determined by Interpace Diagnostics. They have not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing used for clinical purposes. These tests are used for clinical purposes. Tests should not be regarded as investigational or for research. Final diagnosis and optimal patient management are the responsibility of the referring physician or health care provider.


  1. Labourier E, Beaudenon A, Wylie D, Giordano TJ. Multi-categorical testing for miRNA, mRNA and DNA on fine needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology. ENDO 2015. Presented at the 97th Meeting and Expo of the Endocrine Society March 5-8, 2015. SAT-344.
  2. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer statistics review 1975-2011. Section 26. thyroid.
    results_merged/sect_26_thyroid.pdf. Accessed October 1, 2015.
  3. Beaudenon-Huibregtse S, Alexander EK, Guttler RB, et al. Centralized molecular testing for oncogenic gene mutations complements the local cytopathological diagnosis of thyroid nodules. Thyroid. 2014;24(10):1479-1487.
  4. Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab. 2011;96(7): 2016-2206.
  5. Data on File Packet 0001. Interpace Diagnostics. Parsippany, NJ.
  6. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.
  7. Nikiforov YE, Nikiforova MN. Molecular genetics and the diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569-580.
  8. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Thyroid carcinoma Version 2.2014. Available at: Accessed October 1, 2015.
  9. Wang CC, Friedman L, Kennedy GC, et al. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid. 2011;21(3):243-251.